Market brief — August 10, 2026

Friday, markets closed with the CAC 40 at 8,714.93, up 0.17%, the S&P 500 at 7,757.64, up 0.62%, the Nasdaq at 26,690.62, up 1.30%, the DAX at 26,319.45, up 0.69%, and the Euro Stoxx 50 at 6,523.86, up 0.33%. The tape still reads as a risk-on extension led by duration-sensitive growth rather than a broad macro repricing, with the Nasdaq’s outperformance implying that investors finished the week adding exposure to quality growth and rate-sensitive equities instead of de-risking ahead of the weekend.^[1]

The key cross-asset question into Monday is whether that equity bid can coexist with a firmer rates narrative. Reuters’ recent biopharma coverage shows a constructive idiosyncratic backdrop for healthcare and biotech, including Tarsus Pharmaceuticals’ Alkeus acquisition, Moderna’s first FDA approval for an mRNA flu shot, and BioNTech’s chief executive transition, but that is still more a stock-selection catalyst than a regime-changing macro input.^[1] The broader market implication remains that lower real-rate sensitivity is the dominant transmission channel: if Treasury yields stay contained, the rally can keep extending in growth; if yields back up, the leadership mix should narrow quickly.

The Cash Scanner reinforces that view, but with a notable micro-rotation inside risk assets. The strongest signals are concentrated in U.S. healthcare and biotech, where Baxter International scored 41 with a 2.0% gap and ADX 40, Halozyme Therapeutics scored 38 with a 20.2% gap and a breakout above 20 days, and Tandem Diabetes Care also scored 38 with a 19.1% gap and breakout momentum. That cluster suggests active buying in defensive growth and catalyst-heavy names rather than a pure speculative chase. Outside healthcare, Five9 scored 38 with a 19.8% gap and breakout strength, Lyft scored 36 with a 7.1% gap, and First Solar scored 40 with a 2.4% gap and ADX 33, indicating some spillover into higher-beta duration and clean-energy exposure, but the scan is still more US-centric momentum than a broad cyclical rotation.^[1]

Over the next one to five sessions, the dominant narrative is likely to remain “soft-landing plus contained yields,” with investors watching whether last week’s equity strength was genuine macro confirmation or just a short-covering extension. The consensus expects supportive inflation and growth data to justify easier financial conditions; what is already priced in is a good deal of rate relief for long-duration equities; what is less certain is whether the market can absorb any reacceleration in yields without rotation away from mega-cap growth. A credible contrarian scenario is that the recent bid in healthcare, industrials, and selective software names becomes the first sign of a broader leadership handoff if yields rise modestly but not violently.^[1]

The most important upcoming catalysts are the next U.S. inflation print, which will determine whether the rates rally can persist; any Fed communication or commentary that shifts the terminal-rate path; and the next read on Treasury supply and auction demand, which could quickly pressure duration. In Europe, the ECB reaction function remains relevant for CAC 40 and DAX sensitivity, especially if growth data and sovereign curves move together.

The main risks are a renewed backup in real yields, which would hit Nasdaq leadership first; a surprise hawkish tilt in central-bank messaging, which would challenge the current “contained inflation” setup; and any earnings disappointment in high-multiple growth names that forces factor unwinds rather than selective profit-taking.

If the 10-year yield remains pinned and the VIX stays subdued, the path of least resistance favors the Nasdaq, First Solar, and the better-scoring healthcare names such as Halozyme Therapeutics and Baxter International. If yields push higher and breadth deteriorates, watch for the scanner’s breakout names to fade first, with Lyft and Five9 most vulnerable to a momentum reversal. If the next macro release reinforces disinflation, the current equity tone should remain intact; if it does not, the market will likely rotate back toward balance-sheet quality and away from extended duration trades. Bonne journée aux p&l makers.